Albumin–bilirubin grade as a predictor of survival in hepatocellular carcinoma patients with thrombocytopenia

Table 1 Basic characteristics of hepatocellular carcinoma patients

Variables	Overall
Etiology: HBV/others	118/17
Sex: Male/female	113/22
Age (yr)	53.7 ± 9.8
Age: ≥ 60/< 60 yr	37/98
ALT (U/L)	38.0 (26.0-63.2)
AST (U/L)	40.0 (29.4-63.0)
TBIL (µmol/L)	14.8 (11.8-20.1)
ALB (g/L)	38.9 (34.1-42.0)
PLT (109/L)	80 (62-90)
AFP: ≥ 400/< 400 ng/mL	43/92
Ascites: Yes/no	29/106
Tumor size: > 5/≤ 5 cm	64/71
Tumor number: Multiple/single	20/115
Vascular invasion: Yes/no	15/120
Cirrhosis: Yes/no	89/46
CP grade (A/B)	113/22
ALBI score	-2.53 (-2.76 to -2.15)
ALBI grade (1/2-3)	59/76
PALBI score	-2.65 (-2.82 to -2.44)
PALBI grade (1/2-3)	89/46

Data were expressed as median (interquartile range), mean ± SD, or No. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; ALB: Albumin; PLT: Platelet count; AFP: α-fetoprotein; CP: Child–Pugh; ALBI: Albumin–bilirubin; PALBI: Platelet–albumin–bilirubin; HBV: Hepatitis B virus.